An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Cagrilintide/semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 11 Dec 2024 Planned End Date changed from 19 Jan 2026 to 22 Dec 2025.
- 11 Dec 2024 Planned primary completion date changed from 19 Jan 2026 to 22 Dec 2025.
- 11 Dec 2024 Status changed from recruiting to active, no longer recruiting.